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Abstract Gp130 is the common signal transducing receptor
subunit of interleukin (IL)-6, IL-11, leukemia inhibitory factor
(LIF), oncostatin M (OSM), ciliary neurotrophic factor and
cardiotrophin-1. IL-6 and IL-11 induce gp130 homodimerization
whereas the others lead to the formation of heterodimers with
LIFR or OSMR. Binding epitopes for IL-6 and IL-11 are
located in the immunoglobulin-like domain and the cytokine
binding module (CBM). Here we show that a gp130 mutant
lacking domain 1, although unresponsive to IL-6 and IL-11, can
still activate signal transducer and activator of transcription
(STAT) transcription factors in response to LIF or OSM.
Moreover, point mutations in the CBM of gp130 (F191E and
V252D) that severely impair signal transduction in response to
IL-6 and IL-11 differentially interfere with gp130 activation in
response to LIF and OSM. Thus, epitopes involved in gp130
homodimerization are distinct from those leading to the
formation of gp130/LIFR or gp130/OSMR heterodimers. These
findings may serve as the base for rational design of gp130
antagonists that specifically interfere with bioactivity of distinct
IL-6-type cytokines.
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1. Introduction
Cytokines are highly potent mediators mainly involved in
regulation of immune responses and hematopoiesis. Speci¢city
of cytokine action is based on the molecular recognition of the
ligand by its receptor. On the other hand, redundancy of
cytokine action is caused by the fact that di¡erent cytokines
utilize common receptor proteins to trigger the cytoplasmic
signal transduction cascades. This redundancy is particularly
pronounced in the family of interleukin (IL)-6-type cytokines
that all use the transmembrane protein gp130 as signal trans-
ducing receptor component (for review, see [1]). IL-6 [2] and
IL-11 [3], after binding to their speci¢c K-receptors, induce
gp130 homodimerization whereas leukemia inhibitory factor
(LIF)2, oncostatin M (OSM) [4], CNTF [5] and CT-1 [6] sig-
nal via a heterodimer of gp130 and a second signal transduc-
ing receptor protein, the LIFR. OSM can also signal via a
gp130/OSMR heterodimer [7]. The K-receptors can be func-
tionally replaced by the respective soluble receptors lacking
the transmembrane and cytoplasmic parts. Activation of
gp130 homodimers or gp130/LIFR as well as gp130/OSMR
heterodimers results in the phosphorylation of transcription
factors of the signal transducer and activator of transcription
(STAT) family, mainly STAT3. Activated STAT3 dimers
translocate into the nucleus and induce target gene expression
[8].
Gp130, LIFR and OSMR belong to the family of hemato-
poietic cytokine receptors characterized by the presence of at
least one cytokine binding module (CBM) (for review, see [9]).
The extracellular part of gp130 has been predicted to consist
of six individual domains: an Ig-like domain (D1), followed
by a single CBM (D2 and D3) and three ¢bronectin type III-
like domains (D4^D6, Fig. 1) [10]. The main epitopes involved
in recognition of the gp130-homodimerizing cytokines have
recently been de¢ned. Besides critical residues in the CBM
of gp130, the Ig-like domain is required for activation of
gp130 in response to both IL-6 and IL-11 [11^13]. According
to tertiary structure predictions, the ectodomain architecture
of LIFR shows some similarities to the one of gp130 (Fig. 1).
In this study using several gp130 mutants, we investigated
requirements for gp130 activation by the cytokines LIF and
OSM.
2. Materials and methods
2.1. Antibodies and expression vectors
The monoclonal antibodies B-P4 (gp130) and 10B2 (LIFR) were
previously described [14,15]. Construction of gp130 wild-type and mu-
tant expression vectors was described elsewhere [11,13]. The human
full-length LIFR cDNA was cloned into pSBC-1 to yield the mam-
malian expression vector pSBC-LIFR as previously described [16].
2.2. Transfection and analysis of COS-7 cells
COS-7 cells were transiently transfected using the DEAE-dextran
method as described. Cells were cultivated for 48 h prior to stimula-
tion. Mock transfection was performed using 20 Wg pSVL vector. All
other cells were transfected with 10 Wg pSBC-LIFR and 10 Wg of the
respective gp130 construct in pSVL. 48 h after transfection, COS-7
cells were analyzed for receptor expression by FACS as described
[11,13]. For gp130 or LIFR expression, B-P4 and 10B2, respectively,
were used as primary antibodies. R-phycoerythrin-conjugated goat
anti-mouse IgG Fab-fragment was used as a secondary antibody.
2.3. Transfection and analysis of Ba/F3 cells
Ba/F3-gp130 cells and Ba/F3-LIFR cells were transfected by elec-
troporation as described [11,16]. To obtain Ba/F3 cells expressing the
LIFR together with gp130 or the gp130F191E point mutant, Ba/F3-
LIFR cells were coelectroporated with 28 Wg of the respective gp130
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expression vector and 2 Wg of pSV2neo as described. Selected Ba/F3
clones were screened for the presence of membrane-bound gp130 and
LIFR proteins by £ow cytometry using the same antibodies as for
analysis of COS-7 cells.
2.4. Electrophoretic mobility shift assay (EMSA)
48 h after transfection, COS-7 cells were stimulated for 15 min at
37‡C with OSM (4 ng/ml) or LIF (20 ng/ml) or the combination of
IL-6 (12.5 ng/ml) and sIL-6R (500 ng/ml) or left unstimulated. Stably
transfected Ba/F3 cells were stimulated for 15 min at 37‡C with OSM
(50 ng/ml) or LIF (50 ng/ml) or the combination of IL-6 (25 ng/ml)
and sIL-6R (1 Wg/ml) or left unstimulated. Preparation of nuclear
extracts and EMSAs were performed as described [17]. A double-
stranded oligonucleotide derived from the c-fos promoter (m67SIE;
5P-GATCC GGGAG GGATT TACGG GGAAA TGCTG-3P) [18]
was used as 32P-labelled probe. Gels were analyzed using a Phosphor-
Imager (Molecular Dynamics) as well as conventional autoradiogra-
phy.
Fig. 2. STAT1 activation in COS-7 cells transiently transfected with LIFR and either gp130Q or gp130v1Q in response to various cytokines.
(A) 48 h after transfection, cells were analyzed for receptor surface expression by FACS analysis. Cells were incubated with gp130 antibody
B-P4 (left and central panel) or with LIFR antibody 10B2 (right panel) followed by PE-conjugated secondary antibody (black histograms). As
a negative control, mock-transfected cells were treated in the same way (gray open histograms). Representative surface expressions of the recep-
tors are shown. (B) 48 h after transfection, cells were stimulated for 15 min with IL-6 (12.5 ng/ml in the presence of 500 ng/ml sIL-6R), LIF
(20 ng/ml) or OSM (4 ng/ml) or left unstimulated (3) as indicated. Nuclear extracts were prepared and activated STAT1 homodimers were de-
tected by EMSA after binding to a labelled oligonucleotide probe (m67SIE). A representative of three independent experiments is shown.
Fig. 1. Schematic representation of LIFR and gp130Q. The predicted
structural organization of gp130 and LIFR is shown. Black lines in-
dicate conserved cysteine residues, black bars the WSXWS motifs
present in the CBMs. Further domains are assigned as Ig-like (Ig)
or ¢bronectin type III-like (FNIII). Gp130 domains are numbered
from domain 1 (D1) to domain 6 (D6). In the cytoplasmic part of
gp130Q, the amino acid residues following the Janus kinase binding
sites (box 1 and box 2, gray boxes) were replaced by the motif
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3. Results and discussion
3.1. The Ig-like domain of gp130 is required for signal
transduction in response to IL-6, but not in response to LIF
or OSM
Using a gp130 with the STAT recruitment motifs replaced
by the strongly and exclusively STAT1 activating YDKPH
motif derived from the interferon-Q receptor (gp130Q, Fig.
1), we established a system that allows the study of gp130
mutants in COS-7 cells on the background of low levels of
endogenous gp130 [11,13]. To assess the role of the Ig-like
domain of gp130 for receptor activation in response to IL-6,
LIF or OSM, COS-7 cells were transfected with LIFR in
combination with gp130Q or a construct lacking D1
(gp130v1Q). Surface expression of receptors was analyzed by
FACS. Both gp130 variants appear at the cell surface in com-
parable amounts (Fig. 2A, left and central panels). Similarly,
surface expression of transfected LIFR was veri¢ed (Fig. 2A,
right panel).
Mock transfected cells did not respond to stimulation with
the combination of IL-6 and sIL-6R or LIF or OSM (Fig. 2B,
¢rst panel). Cells transfected with gp130Q alone showed acti-
vation of STAT1 homodimers after stimulation with IL-6 and
OSM, but not with LIF (Fig. 2B, second panel). COS-7 cells
express on their cell surface low levels of endogenous OSMR,
while no endogenous LIFR could be detected by FACS anal-
ysis (data not shown). This leads to the conclusion that in the
case of OSM stimulation, STAT activation observed in cells
transfected with gp130Q constructs is due to heterodimers of
gp130 with OSMR.
To analyze the e¡ect of the mutants in response to LIF,
LIFR was cotransfected with the gp130Q constructs. Stimula-
tion of LIFR and gp130Q-transfected cells with IL-6, OSM or
LIF leads to a robust activation of STAT1 (Fig. 2B, fourth
panel). The STAT1 activation in response to LIF or OSM is
not due to overexpression of LIFR in these cells, as cells
transfected with LIFR alone showed only a very weak re-
sponse after LIF stimulation and no response after stimula-
tion with OSM (Fig. 2B, third panel). When COS-7 cells were
transfected with LIFR and gp130v1Q, the response to IL-6
was reduced to background levels whereas the LIF signal
remained largely una¡ected (Fig. 2B, ¢fth panel). The re-
sponse to OSM in these cells was slightly reduced compared
to cells stimulated with LIF. In cells transfected with
Fig. 3. Location of the point mutations in the CBM of gp130. Ami-
no acid side-chains targeted by site-directed mutagenesis are shown
in a ribbon presentation of the gp130 CBM based on the X-ray
structure by Bravo et al. [20]. F191 is located in the E^F-loop of
D2, E195 is located in strand F of D2 and V252 as well as I254 are
located in the B^C-loop of D3.
Fig. 4. STAT1 activation in COS-7 cells transiently transfected with
LIFR and gp130Q point mutants in response to various cytokines.
(A) 48 h after transfection, cells were analyzed for receptor surface
expression by FACS analysis. Cells were incubated with gp130 anti-
body B-P4 followed by PE-conjugated secondary antibody (black
histograms). As a negative control, mock-transfected cells were
treated in the same way (gray open histograms). Analysis for LIFR
surface expression was performed as described in Fig. 2A and gave
comparable results as shown there. (B) 48 h after transfection, cells
were stimulated for 15 min with IL-6 (12.5 ng/ml in the presence of
500 ng/ml sIL-6R), LIF (20 ng/ml) or OSM (4 ng/ml) or left un-
stimulated (3) as indicated. Nuclear extracts were prepared and ac-
tivated STAT1 homodimers were detected by EMSA after binding
to a labelled oligonucleotide probe (m67SIE). A representative of
three independent experiments is shown.
FEBS 23349 15-2-00
A. Timmermann et al./FEBS Letters 468 (2000) 120^124122
gp130v1Q alone, the response to OSM was comparable to that
of cells transfected with gp130v1Q and LIFR (data not
shown).
The Ig-like domain of gp130 plays a crucial role in the
formation of the signal transducing complex in response to
IL-6 as well as IL-11 [12,13]. The model of the hexameric
IL-6 receptor complex assigns as binding partners for the
three binding sites on IL-6 the CBM of IL-6R for site I,
the CBM of gp130 for site II and the Ig-like domain of a
second gp130 molecule for site III, with the Ig-like domains
functioning as bridges between the two IL-6/IL-6R/gp130
trimers in this complex [19]. Signal transduction in response
to LIF is independent of the Ig-like domain of gp130. Site
II of LIF is postulated to interact with the gp130 CBM
whereas site III contacts the LIFR Ig-like domain. A
similar trimeric complex has been suggested for the signal
transducing complex of gp130 and OSMR [12], as OSMR
also contains an Ig-like domain located N-terminal of the
CBM. Therefore, the Ig-like domain of gp130 is not required
for receptor complex formation in response to both LIF and
OSM.
3.2. Residues in the gp130 CBM critical for IL-6
responsiveness di¡erentially contribute to activation by LIF
or OSM
When the importance of amino acids F191 and V252 in the
gp130 CBM for receptor activation in response to IL-6 and
IL-11 was established [11,13], no structural data on the gp130
ectodomain were available. In the mean time, the crystal
structure of the gp130 CBM [20] as well as the solution struc-
ture of D3 have been solved [21]. Fig. 3 shows the positions of
the amino acids selected for mutagenesis in the X-ray struc-
ture of gp130 con¢rming their location predicted from our
molecular model [22].
COS-7 cells were transfected with the gp130Q point mutants
gp130F191EQ, gp130E195KQ, gp130V252DQ or gp130I254DQ
in combination with LIFR. Transfected cells were analyzed by
FACS, indicating that the introduced point mutations do not
interfere with cell surface expression of receptor mutants (Fig.
4A). As the antibody B-P4 used for detection of gp130 mu-
tants recognizes an epitope within the membrane-proximal
part (D4^D6), recognition of gp130 by this antibody is not
altered due to introduction of the point mutations.
Fig. 5. STAT1 and STAT3 activation in Ba/F3 cells stably transfected with LIFR in combination with gp130 or the mutant gp130F191E in re-
sponse to various cytokines. (A) Ba/F3 cells stably transfected with gp130, LIFR, or the combination of either LIFR and gp130 or LIFR and
gp130F191E were analyzed for receptor surface expression by FACS analysis. Cells were incubated with gp130 antibody B-P4 or with LIFR
antibody 10B2 followed by PE-conjugated secondary antibody (light and dark gray open histograms, respectively). As a negative control, cells
were incubated with PE-conjugated secondary antibody alone (black histograms). (B) Stably transfected Ba/F3 cells were stimulated for 15 min
with IL-6 (25 ng/ml in the presence of 1 Wg/ml sIL-6R), LIF (50 ng/ml) or OSM (50 ng/ml) or left unstimulated (3) as indicated. Nuclear ex-
tracts were prepared and activated STAT dimers were detected by EMSA after binding to a labelled oligonucleotide probe (m67SIE). A repre-
sentative of three independent experiments is shown.
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Cells transfected with gp130F191EQ and gp130V252DQ
showed no STAT activation upon stimulation with IL-6/IL-
6R complexes. In gp130I254DQ-transfected cells, the response
is reduced while gp130F195KQ-transfected cells served as a
positive control (Fig. 4B). These ¢ndings are in line with the
previously de¢ned role of these amino acids in receptor acti-
vation by IL-6 or IL-11 [13]. None of the introduced point
mutants severely a¡ected signal intensity upon LIF stimula-
tion. Upon OSM stimulation, gp130F195KQ, gp130V252DQ
and gp130I254DQ mutants show STAT activation comparable
to that after LIF stimulation. The gp130F191EQ mutant how-
ever does not respond to OSM. In cells transfected with the
gp130Q mutants alone, the OSM response was comparable to
that of cells cotransfected with gp130Q mutants and LIFR
(data not shown). Thus, residues in the CBM required for
gp130 activation in response to IL-6 and IL-11 are not neces-
sarily crucial for gp130 activation in response to LIF or OSM.
To analyze whether the observed response of gp130 point
mutants after stimulation with LIF or OSM depends on the
cellular environment, Ba/F3 cells were stably transfected with
LIFR, gp130 or a combination of either LIFR and gp130 or
LIFR and the gp130F191E point mutant, respectively. Ba/F3
cells express gp130 or LIFR only after transfection of the
respective cDNAs (Fig. 5A). Untransfected cells or cells trans-
fected with LIFR alone do not show activation of STAT
factors in response to any of the analyzed cytokines (Fig.
5B, ¢rst and third panel). Cells transfected with gp130 alone
only respond to IL-6/sIL-6R but not to LIF or OSM (Fig. 5B,
second panel). Cells expressing the LIFR together with gp130
show a prominent STAT activation after stimulation with all
three cytokines analyzed (Fig. 5B, fourth panel). In contrast,
cells expressing LIFR in combination with the gp130F191E
mutant show a considerable STAT activation only after stim-
ulation with LIF but no response to stimulation with IL-6/
sIL-6R or OSM (Fig. 5B, ¢fth panel). These ¢ndings are in
accordance with the observations made with transiently trans-
fected COS-7 cells.
According to our model, site II of IL-6 interacts with the
CBM of one gp130 in the signal transducing complex [22].
LIF and OSM are as well postulated to bind to the gp130
CBM. Thus, di¡erent requirements exist for binding of the
analyzed cytokines to the gp130 CBM. In a previous study,
monoclonal antibodies against the gp130 ectodomain that se-
lectively interfere with the activation of gp130 by IL-6-type
cytokines have been characterized [14]. The selectivity of some
of these antagonistic antibodies that maps to the gp130 CBM
(Mu«ller-Newen, unpublished observation) can be explained in
the light of our present ¢ndings.
The CBM is the structural hallmark of hematopoietic cyto-
kine receptors [9]. These receptors are either monospeci¢c (e.g.
EpoR, GHR, G-CSFR) or recognize several ligands (gp130;
the common L-chain of the receptors for GM-CSF, IL-3 and
IL-5; the common Q-chain of the receptors for IL-2, IL-4, IL-
7, IL-9 and IL-15). In the case of the common L-chain, it has
also been found that several mutations in the CBM di¡eren-
tially interfere with ligand recognition [23]. Thus, although the
role of the CBMs in ligand binding is evolutionary conserved,
the molecular details of ligand recognition diverge. These ¢nd-
ings may serve as a base for the development of antagonists
that speci¢cally block the activity of a distinct cytokine that
signals via one of the promiscuous cytokine receptors.
Recently, it has been suggested that gp130 may exist in
preformed homo- or heterodimers (with LIFR or OSMR)
on the cell surface which are then activated by the ligand
[24]. In this model, such dimers would be a mandatory requi-
site for the induction of signal transduction. According to this
scenario, the mutations of gp130 presented here would not
only in£uence ligand binding but also prevent the preforma-
tion of homo- but not of heterodimers. Further studies are
needed to give a more detailed insight into the activation
mechanism of these receptors.
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